http://api.archives-ouvertes.fr/search/?fq=halId_s:hal-01718184&fl=title_s,en_title_s,docid,label_s,en_label_s,docType_s,authIdHal_s,halId_s,structId_i,uri_s,keyword_s,en_keyword_s,authLastNameFirstName_s,journalTitle_s,abstract_s,en_abstract_s,producedDate_tdate,producedDateY_i,language_s,fileMain_s&sort=publicationDate_s+desc
authors
- Greenwood John
- Hammarlund-Udenaes Margareta
- Jones Hazel C.
- Stitt Alan W.
- Vandenbroucke Roosmarijn E.
- Romero Ignacio A.
- Campbell Matthew
- Fricker Gert
- Brodin Birger
- Manninga Heiko
- Gaillard Pieter J.
- Schwaninger Markus
- Webster Carl
- Wicher Krzysztof B.
- Khrestchatisky Michel
keywords
- Animals
- Humans
- Blood-Brain Barrier
- Central Nervous System
- Neuroinflammation
- Antibody therapy
- Blood–CSF barrier
- Blood–retinal barrier
- Drug delivery
- Liposomal technology
- MicroRNA
- Nervous System Diseases
- Protein capsules
- Viral vectors
document type
ART
abstract
This is a report on the CNS barrier congress held in London, UK, March 22-23rd 2017 and sponsored by Kisaco Research Ltd. The two 1-day sessions were chaired by John Greenwood and Margareta Hammarlund-Udenaes, respectively, and each session ended with a discussion led by the chair. Speakers consisted of invited academic researchers studying the brain barriers in relation to neurological diseases and industry researchers studying new methods to deliver therapeutics to treat neurological diseases. We include here brief reports from the speakers.
more information